1. Xiaoguang Qiu#,Yidong Chen#, Zhaoshi Bao,Li Chen, Tao Jiang.Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study.Radiotherapy and Oncology.2022.167 .1-6.SCI |
2. Qiu XG#, Chen YD#, Yuan J, Zhang N, Lei T, Liu J, Yang M .Functional BCL-2 rs2279115 Promoter Noncoding Variant Contributes to Glioma Predisposition, Especially in Males..DNA Cell Biol.2019.38(1).85-90.SCI |
3. Chen YD, Zhang NS, Qiu XG, Yuan JP, Yang M.LncRNA CDKN2BAS rs2157719 genetic variant contributes to medulloblastoma predisposition.Journal of Gene Medicine.2018.20(1). .SCI |
4. Chen YD, Qiu XG, Feng J, Li WB..Long-term outcomes of adjuvant radiotherapy after surgical resection of central neurocytoma..Radiation Oncology.2014.9(1).242.SCI |
5. Lu C#, Chen YD#, Han S, Wei J, Ge Y, Pan W, Jiang T, Qiu XG, Yang M.A RAD52 genetic variant located in a miRNA binding site is associated with glioma risk in Han Chinese.J Neurooncol.2014.20(1).11-14.SCI |
6. Chen YD, Lu C, Wei J, Han S, Wang H, Jiang T, Qiu XG, Yang M.1p34.2 rs621559 and 14q21 rs398652 leukocyte telomere length-related genetic variants contribute to glioma susceptibility.J Neurooncol.2014.119(1).71-8.SSCI |
7. Chen YD, Zhang X, Qiu XG, Li J, Yuan Q, Jiang T, Yang M.Functional FEN1 genetic variants and haplotypes are associated with glioma risk.J Neurooncol.2013.111.145-51.SCI |
8. Chen YD, Feng J, Fang T, Yang M, Qiu XG, Jiang T.Effect of intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy on clinical outcomes in patients with glioblastoma multiforme..Chin Med J (Engl).2013.126(12).2320-4.SCI |
9. Chen YD, Feng QF, Lu HZ, Mao YS, Zhou ZM, Ou GF, Wang M, Zhao J, Zhang HX, Xiao ZF, Chen DF, Liang J, Zhai YR, Wang LH, He J.Role of adjuvant radiotherapy for stage II thymoma after complete tumor resection. Int J Radiat Oncol Biol Phys.2010.78.1400-6.SCI |